* Marker Therapeutics Inc MRKR.OQ MRKR.O is expected
to report
resultson August 12 (estimated) for the period ending June
30 2024
*
* LSEG's mean analyst estimate for Marker Therapeutics Inc
is for
a loss of 43 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Marker
Therapeutics Inc is $11.75, above its last closing price
of $3.86.
This summary was machine generated August 9 at 11:46 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)